Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

10.5%

2 terminated/withdrawn out of 19 trials

Success Rate

89.5%

+3.0% vs industry average

Late-Stage Pipeline

53%

10 trials in Phase 3/4

Results Transparency

82%

14 of 17 completed trials have results

Key Signals

14 with results

Enrollment Performance

Analytics

Phase 3
7(53.8%)
Phase 4
3(23.1%)
Phase 1
3(23.1%)
13Total
Phase 3(7)
Phase 4(3)
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials
NCT03370172Phase 1Completed

A Study of BAX 888 in Male Adults With Severe Hemophilia A

Role: collaborator

NCT02078427Completed

ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)

Role: collaborator

NCT05059977Phase 1Completed

A Study of TAK-881 in Healthy Adults

Role: collaborator

NCT04578535Phase 1Completed

A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants

Role: collaborator

NCT03277313Phase 3Completed

Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects

Role: collaborator

NCT05363358Completed

A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Role: collaborator

NCT02764489Phase 3Completed

FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)

Role: collaborator

NCT03116347Phase 4Completed

Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects

Role: collaborator

NCT03565237Phase 4Completed

RIXUBIS PMS India (RIXUBIS PMS)

Role: collaborator

NCT03199794Completed

Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice

Role: collaborator

NCT02895945Phase 3Terminated

BAX 802 in CHA With Inhibitors

Role: collaborator

NCT02973087Phase 3Completed

rVWF IN PROPHYLAXIS

Role: collaborator

NCT02610127Completed

Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A

Role: collaborator

NCT02585960Phase 3Completed

BAX 855 PK-guided Dosing

Role: collaborator

NCT01945593Phase 3Completed

BAX 855 Continuation

Role: collaborator

NCT00357656Phase 4Completed

Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery

Role: collaborator

NCT02722304Phase 3Terminated

Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency

Role: collaborator

NCT02556775Completed

Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia

Role: collaborator

NCT03716700Completed

Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)

Role: collaborator

All 19 trials loaded